Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest

Initial search results include only NCI-sponsored clinical trials. To search all trials, click the "REFINE SEARCH" button, scroll down to the Trial ID/Sponsor section and select the "All" check box in the Sponsor of Trial section.

View Content for:
Display:
?
Cancer Type/Condition:  Bladder cancer
Trial Type:  Treatment
Trial Status:  Active
Results 1-25 of 145 for your search:
Start Over
Safety Study of Bipolar Versus Monopolar Transurethral Resection of Bladder Tumors
Phase: Phase IV
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: URO-OBT-01, NCT01446822
Effect of TachoSil® on Incidence of Symptomatic and Radiographic Lymphoceles After Extended Pelvic Lymph Node Dissection in Prostate and Bladder Cancer.
Phase: Phase IV
Type: Supportive care, Treatment
Status: Active
Age: Over 18
Sponsor: Other
Protocol IDs: EC/2013/472, 2013-000782-36, NCT02001857
Value of Immediate Post-operative Intravesical Epirubicin in Intermediate&High Risk Non Muscle Invasive Bladder Cancer
Phase: Phase IV
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: AEl-Sawy172014, NCT02214602
Treatment of Locally Advanced or Metastatic Transitional Cell Carcinoma With Cabazitaxel
Phase: Phase III, Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: RRK4368, 2012-002552-16, NCT01668459
Cabazitaxel vs. Vinflunine in Metastatic or Locally Advanced Transitional Cell Carcinoma of the Urothelium (TCCU)
Phase: Phase III, Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: Secavin-12, NCT01830231
A Study Evaluating Chemotherapy With Fractionated Cisplatin/Gemcitabine Versus Carboplatin/Gemcitabine in the Treatment of Advanced or Metastatic Urothelial Cancer With Impaired Renal Function.
Phase: Phase III, Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: 13 URO 02, NCT02240017
Adjuvant Versus Progression-Triggered Gemcitabine Monotherapy for Locally Advanced Bladder Cancer
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: B9E-MC-S062, AB 22/00, NCT00146276
Selenium in Preventing Cancer Recurrence in Patients With Bladder Cancer
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: CDR0000602239, UZG-CUL-UHG-Non-InvasiveBladde, EU-20870, UZG-CUL-UHG-Non-InvasiveBladderCancer, CUL-UHG-Non-Invasive Bladder Cancer, NCT00729287
S1011 Standard or Extended Pelvic Lymphadenectomy in Treating Patients Undergoing Surgery for Invasive Bladder Cancer
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: S1011, SWOG-S1011, NCT01224665
Clinical Trial Using Bipolar Technology for Transurethral Resection of Bladder Tumor
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: CUHK_TURB_2012, NCT01581723
Fluorescence Cystoscopy and Optimized MMC in Recurrent Bladder Cancer (FinnBladder 9)
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: FinnBladder 9, 2012-000559-15, NCT01675219
Perioperative Chemotherapy for Patients With Locally Advanced Bladder Cancer
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 to 80
Sponsor: Other
Protocol IDs: 2011/119/HP, NCT01812369
Therapeutic Instillation of Mistletoe
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 to 80
Sponsor: Pharmaceutical / Industry
Protocol IDs: AB03, 2013-003446-16, NCT02106572
A Study of Pembrolizumab (MK-3475) Versus Paclitaxel, Docetaxel, or Vinflunine for Participants With Advanced Urothelial Cancer (MK-3475-045/KEYNOTE-045)
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: 3475-045, 2014-002009-40, NCT02256436
A Study of MPDL3280A Compared With Chemotherapy in Patients With Locally Advanced or Metastatic Urothelial Bladder Cancer
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: GO29294, 2014-003231-19, NCT02302807
A Study of Ramucirumab (LY3009806) Plus Docetaxel in Participants With Urothelial Cancer
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Status: Approved-not yet active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: 15679, I4T-MC-JVDC, 2014-003655-66, NCT02426125
Eribulin Mesylate in Treating Patients With Locally Advanced or Metastatic Cancer of the Urothelium and Kidney Dysfunction
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-2009-00170, CDR0000492014, PHII-75, 7435, N01CM00038, N01CM00071, N01CM62201, N01CM62209, P30CA033572, U01CA062505, CCC-PHII-75, NCI-7435, NCT00365157
Phase I & II Trial of Intravesicular Abraxane for Treatment-refractory Bladder Cancer
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: Over 18
Sponsor: Other
Protocol IDs: AAAC1114, NCT00583349
Image-Guided Tumorboost of Bladder Cancer
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: CIRRO IP 070109 DaBlaCa-1, M-20080210, NCT00963404
A Study of BBI608 Administered With Paclitaxel in Adult Patients With Advanced Malignancies
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: BBI608-201, NCT01325441
A Study of ALT-801 in Combination With Cisplatin and Gemcitabine in Muscle Invasive or Metastatic Urothelial Cancer
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: NCI, Pharmaceutical / Industry
Protocol IDs: CA-ALT-801-01-10, NCT01326871
A Study of ALT-801 in Patients With Bacillus Calmette-Guerin (BCG) Failure Non-Muscle Invasive Bladder Cancer
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CA-ALT-801-01-12, NCT01625260
Sirolimus, Cisplatin, and Gemcitabine Hydrochloride in Treating Patients With Bladder Cancer
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: 8027, NCI-2013-01614, P30CA015704, NCT01938573
Phase 1/2 Study of ABI-009 in Nonmuscle Invasive Bladder Cancer
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: Over 18
Sponsor: NCI, Pharmaceutical / Industry
Protocol IDs: BC001, 1R42CA171552-01, NCT02009332
Start Over